Open Access. Powered by Scholars. Published by Universities.®

Biochemistry, Biophysics, and Structural Biology Commons

Open Access. Powered by Scholars. Published by Universities.®

Molecular Biology

University of South Florida

Galectin-1

Articles 1 - 2 of 2

Full-Text Articles in Biochemistry, Biophysics, and Structural Biology

Significance Of Pten Phosphorylation And Its Nuclear Function In Lung Cancer, Prerna Malaney Nov 2016

Significance Of Pten Phosphorylation And Its Nuclear Function In Lung Cancer, Prerna Malaney

Graduate Theses and Dissertations

Phosphorylation mediated inactivation of PTEN leads to multiple malignancies with increased severity. However, the consequence of such inactivation on downstream functions of PTEN are poorly understood. Therefore, the objective of my thesis is to ascertain the molecular mechanisms by which PTEN phosphorylation drives lung cancer. PTEN phosphorylation at the C-terminal serine/threonine cluster abrogates its tumor suppressor function. Despite the critical role of the PTEN C-tail in regulating its function, the crystal structure of the C-tail remains unknown. Using bioinformatics and structural analysis, I determined that the PTEN C-tail is an intrinsically disordered region and is a hot spot for ...


Contribution Of Epithelial Hypoxia Signaling To Pulmonary Fibrosis: Role Of Fak1 And Galectin-1 As Driver Molecules, Jaymin J. Kathiriya Oct 2016

Contribution Of Epithelial Hypoxia Signaling To Pulmonary Fibrosis: Role Of Fak1 And Galectin-1 As Driver Molecules, Jaymin J. Kathiriya

Graduate Theses and Dissertations

Idiopathic Pulmonary Fibrosis (IPF) is a deadly disease of unknown origin, which causes 80,000 deaths every year in the US and Europe combined. Unknown etiology and late diagnosis, combined with limited treatment options, contribute to a dismal survival rate of 3-5 years post diagnosis. Although molecular mechanisms underlying IPF pathogenesis and progression have been studied for over two decades, lack of in vivo models that recapitulate chronic, progressive, and irreversible nature of IPF have contributed to limited therapeutic success in clinical trials. Currently, only two drugs, Pirfenidone and Nintedanib, are approved for IPF treatment in the US, with their ...